Table 2.

Most commonly reported characteristics of eligible studies (n = 81)*

Study Characteristic	n (%)
Randomized Trial n (%)	80 (98.8)
Number Treatment Arms
2	52 (64.2)
3	20 (24.7)
Clinical Phase
2	17 (21.0)
3	61 (75.3)
Pharmacological intervention	81 (100.00)
Trial Type
Non-inferiority	8 (9.9)
Superiority	67 (82.7)
Commercial Status
Industry sponsored	76 (93.8)

^*81 protocols were eligible for review. Only selected results are shown in some categories, so sub-categories may not sum to 81. Full results are given in Supplement File 2, Table 2